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   STABILITY-INDICATING HPLC 
DETERMINATION OF CIPROFIBRATE IN 
BULK DRUG AND PHARMACEUTICAL 
DOSAGE FORM 
A novel stability-indicating high-performance liquid chromatographic assay me-
thod was developed and validated for quantitative determination of ciprofibrate 
in bulk drugs and in pharmaceutical dosage form in the presence of degra-
dation products. An isocratic, reversed phase HPLC method was developed to 
separate the drug from the degradation products, using an Ace5-C18 (250 
mm×4.6 mm, 5 μm) advanced chromatography column, and methanol and wa-
ter (90:10 v/v) as a mobile phase. The detection was carried out at a wave-
length of 232 nm. The ciprofibrate was subjected to stress conditions of hydro-
lysis (acid and base), oxidation, photolysis and thermal degradation. Degrada-
tion was observed for ciprofibrate in base, in acid and in 30% H2O2. The drug 
was found to be stable in the other stress conditions attempted. The degrada-
tion products were well resolved from the main peak. The percentage recovery 
of ciprofibrate was from (98.65 to 100.01%) in the pharmaceutical dosage 
form. The developed method was validated with respect to linearity, accuracy 
(recovery), precision, system suitability, specificity and robustness. The forced 
degradation studies prove the stability indicating power of the method. 
Keywords: ciprofibrate; HPLC; validation; stability; degradation. 
 
 
Ciprofibrate, chemically 2-[4-(2,2-dichlorocyclo-
propyl)phenoxy]-2-methylpropanoic acid (Figure 1), is 
used to treat hyperlipidaemia. PPARα activators have 
been documented to lower plasma triglycerides and 
cholesterol levels by decreasing elevated fibrinogen 
and PAI-1 levels and elevate the level of plasma HDL 
cholesterol [1-5].Therefore, it is beneficial in the pre-
vention of ischemic heart disease in individuals with 
elevated levels of LDL cholesterol. 
Various methods for the analysis of ciprofibrate 
in bulk and pharmaceutical formulation individually 
and in combination have been reported, such as: de-
termination of benzafibrate and ciprofibrate in phar-
maceutical formulations by densitometry and video- 
-densitometry TLC, determination of cholesterol de-
creasing fibrates by chromatographic methods, deter-
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mination of benzafibrate, ciprofibrate and fenofibric 
acid in human plasma by high-performance liquid 
chromatography, separation of fibrate-type antihyper-
lipidemic drugs by capillary electrophoresis, study of 
liquid chromatography retention of some fibrate-type 
antihyperlipidemic drugs on C~1~8 and CN columns, 
the enantiomeric resolution of ciprofibrate and related 
compounds by HPLC using chiral stationary phase, 
achiral and chiral determination of ciprofibrate and its 
glucuronide in human urine by capillary electropho-
resis, ciprofibrate quantification in human plasma by 
high-performance liquid chromatography coupled with 
electrospray tandem mass spectrometry for pharma-
cokinetic studies, HPLC, TLC densitometry and capil-
lary electrophoresis [6-13]. According to current good 
manufacturing practices, all drugs must be tested with 
a stability-indicating assay method before release. To 
date, no stability-indicating HPLC assay method for 
the determination of ciprofibrate is available in the lite-
rature. It was felt necessary to develop a stability indi-
cating liquid chromatography (LC) method for the de-
termination of ciprofibrate as bulk drug and pharma-
ceutical dosage form and separate the drugs from the P.S. JAIN et al.: STABILITY-INDICATING HPLC DETERMINATION OF CIPROFIBRATE…  CI&CEQ 18 (1) 95−101 (2012) 
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degradation products under the International Confe-
rence on Harmonization (ICH) suggested conditions 
(hydrolysis, oxidations, photolysis and thermal stress) 
[14,15]. Therefore, the aim of the present study was 
to develop and validate a stability-indicating HPLC as-
say method for ciprofibrate as bulk drug and in phar-
maceutical dosage form as per ICH guidelines [15]. 
 
Figure 1. Chemical structure of ciprofibrate. 
EXPERIMENTAL 
Materials and reagents 
Ciprofibrate bulk drug (purity 99.8%) and tablet 
ciprofibrate (100 mg) were obtained from Glenmark 
Pharmaceuticals (Nasik, India). Hydrochloric acid and 
sodium hydroxide pellets were obtained from Rankem 
Laboratories India. Methanol and o-phosphoric acid 
were obtained from Merck Specialities Private Ltd. 
Hydrogen peroxide was obtained from Fischer Sci-
entific, India. All chemicals used were of HPLC grade. 
Milli-QWater was used throughout the experiment.  
Chromatographic condition 
The HPLC system used was a Shimadzu sys-
tem equipped with a photodiode array detector. A 
chromatographic column of 250 mm length and inter-
nal diameter of 4.6 mm filled with octadecyl silane 
Ace5-C18 (Advanced Chromatography Technology, 
USA) stationary phase with particle size 5 μm were 
used. The instrumental setting was at a flow rate of 1 
mL min
-1. The injection volume was 20 μL. The detec-
tion wavelength was 232 nm.  
Mobile phase 
The mobile phase consisted of methanol and 
water in the ratio 90:10 v/v. The pH 3.7 of mobile 
phase was adjusted with o-phosphoric acid in double 
distilled water. The mobile phase was premixed and 
filtered through a 0.45 μm nylon filter and degassed. 
Preparation of standard stock solutions 
All solutions were prepared on a weight basis 
and solution concentrations were also measured on 
weight basis to avoid the use of an internal standard. 
Standard solution of ciprofibrate was prepared by dis-
solving the drugs in the diluents and diluting them to 
the desired concentration. Diluent A was composed of 
methanol and diluent B was composed of water in the 
ratios of 90:10 v/v. Approximately 5 mg of ciprofibrate 
was accurately weighed, transferred in a 50 mL vo-
lumetric flask, dissolved and diluted to 50 mL with the 
diluent A. From these stock solutions, 2 mL of cipro-
fibrate standard solution were transferred in a 10 mL 
volumetric flask and diluted with diluent B. This final 
solution contained 20 μg mL
-1 of ciprofibrate. 
Sample solution (tablets) 
Ten tablets of ciprofibrate (100 mg) were finely 
ground using agate mortar and pestle. The ground 
material, which was equivalent to 10 mg of the active 
pharmaceutical ingredient, was extracted into diluent 
A in a 25 mL volumetric flask by vortex mixing fol-
lowed by ultrasonication. 2 mL of the solution was di-
luted to 40 mL with diluent B. The solution was filtered 
through a 0.45 μm nylon filter and an appropriate con-
centration of sample (20 μg mL
-1 assay concentration) 
was prepared at the time of analysis. 
Procedure for forced degradation study 
Stability testing is an important part of the pro-
cess of drug product development. The purpose of 
stability testing is to provide evidence of how the 
quality of a drug substance or drug product varies 
with time under a variety of environmental conditions, 
for example temperature, humidity, and light and en-
ables recommendation of storage conditions, retest 
periods, and shelf life to be established. The two main 
aspects of drug product that play an important role in 
shelf-life determination are assay of the active drug 
and the degradation products generated during stabi-
lity studies. 
Preparation of sample solution 
Acidic degradation. 5 mg of drug was dissolved 
in 5 mL of diluent A, and 50 mL of 3 M hydrochloric 
acid was added. The solution was kept for 1 h, after 
which 10 mL of solution was neutralized with 3 M so-
dium hydroxide. The solution was then diluted with di-
luent B to prepare a working solution of 20 μg mL
-1 
(pH of solution was 2.3). 
Alkaline degradation.  5 mg of drug was dis-
solved in 5 mL of diluent A, and 50 mL of 0.5 M so-
dium hydroxide was added. The solution was kept for 
1 h, after which 10 mL of solution was neutralized with 
0.5 M hydrochloric acid. The solution was then diluted 
with diluent B to prepare a working solution of 20 μg 
mL
-1 (pH of solution was 14). 
Oxidative degradation.  5 mg of drug was dis-
solved in 5 mL of diluent A, and 50 mL of 30% H2O2 P.S. JAIN et al.: STABILITY-INDICATING HPLC DETERMINATION OF CIPROFIBRATE…  CI&CEQ 18 (1) 95−101 (2012) 
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was added. The solution was kept for 4 h. The solu-
tion was then diluted with diluent B to prepare a work-
ing solution of 20 μg mL
-1. 
Thermal degradation. 10 mg of drug was kept in 
the hot air oven for 48 h at 100 °C. The working so-
lution was then prepared using diluents A and B. 
Photodegradation. 10 mg of drug was exposed 
to the short wavelength (254 nm) and long wave-
length (366 nm) UV light for 48 h. The working solu-
tion was then prepared using diluents A and B. 
Specificity 
Specificity is the ability of the method to unequi-
vocally assess the analyte in the presence of com-
ponents, which may be expected to be present. Typi-
cally, these might include degradation products, mat-
rix, etc. [15]. The specificity study of the developed 
HPLC method for ciprofibrate was carried out in the 
presence of its degradation products. Stress studies 
were performed for ciprofibrate bulk drug to provide 
an indication of the stability indicating property and 
specificity of the proposed method. Intentional degra-
dation was attempted to stress conditions exposing it 
to acid (3 M hydrochloric acid), alkali (0.5 M NaOH), 
hydrogen peroxide (30%), heat (100 °C) and UV light 
(254 and 366 nm wavelength) to evaluate the ability 
of the proposed method to separate ciprofibrate from 
its degradation products. For the light and heat stu-
dies, the study period was 48 h, whereas the study 
period was 1 h for acid and base, and 4 h for oxide-
tion studies. Peak purity testing for ciprofibrate was 
done by using a PDA detector in stress samples. 
RESULTS AND DISCUSSION 
Optimization of chromatographic conditions 
The primary target in developing this stability 
indicating HPLC method is to achieve the resolution 
between ciprofibrate and its degradation products. To 
achieve the separation of degradation products we 
used a stationary phase C-18 and combination of mo-
bile phase methanol and water (90:10 v/v). The sepa-
ration of the degradation product and ciprofibrate was 
achieved on Ace5 octadecyl silane C-18 stationary 
phase and methanol and water (90:10 v/v) as a mo-
bile phase. The tailing factor obtained was less than 
two and retention time was about 3.3 min for the main 
peak, and less than 4 min for the degradation pro-
ducts, which would reduce the total run time and 
ultimately increase the productivity thus reducing the 
cost of analysis per sample. Forced degradation study 
showed the method is highly specific and entire deg-
radation products were well resolved from the main 
peak. The developed method was found to be specific 
and the method was validated as per  international 
guidelines. 
Result of forced degradation experiments 
Degradation was not observed for ciprofibrate 
samples during stress conditions like heat, UV and 
light, but was observed in base, acid and oxidation 
studies. Ciprofibrate was degraded in acid (Figure 2), 
base (Figure 3) and by oxidation (Figure 4) and for-
med polar impurities. The observed degradation of 
ciprofibrate was 7.54% in acidic conditions, 4.88% in 
basic condition after 1 h, and 58.70% after 4 h under 
 
Figure 2. Chromatogram of ciprofibrate in acid degradation (acid degraded product (2.4 min) and ciprofibrate (3.3 min)). 
Concentration of ciprofibrate injected was 20 μg mL
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oxidation conditions. Peak purity results greater than 
990 indicate that the ciprofibrate peak is homoge-
neous in all stress conditions tested. The unaffected 
assay of ciprofibrate in the tablets confirms the sta-
bility indicating power of the method (Table 1). 
Determination of active ingredients in tablets 
The contents of drug in tablets were determined 
by the proposed method using the calibration curve. 
Method validation 
Precision 
Method precision (intra-day precision) was eva-
luated by carrying out six independent assays of cip-
rofibrate test samples against a reference standard. 
The percentage of RSD of six assay values obtained 
was calculated. The intermediate precision (inter-day 
precision) of the method was also evaluated using 
 
Figure 3. Chromatogram of ciprofibrate in base degradation (base degraded product (2.4 min) and ciprofibrate(3.3 min)). 
 
Figure 4. Chromatogram of ciprofibrate in oxidative degradation (oxidative degraded product (2.4 min) and ciprofibrate (3.3 min)). 
Table 1. Summary of forced degradation results 
Stress conditions   Time, h   Assay of active substance  Degradation, %  Peak purity
a 
Acid hydrolysis (3 mol L
-1 HCl)   1  90.24  7.54  999 
Base hydrolysis (0.5 mol L
-1 NaOH)  1  88.69  4.88  999 
Oxidation (30% H2O2) 4  40.08  58.70  999 
Thermal (100 °C)   48  99.88  No degradation  999 
Photo 48  99.65  No  degradation  999 
aPeak purity values in the range of 990-1000 indicate the homogenous peak [16] P.S. JAIN et al.: STABILITY-INDICATING HPLC DETERMINATION OF CIPROFIBRATE…  CI&CEQ 18 (1) 95−101 (2012) 
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two different analysts, different HPLC systems and 
different days in the same laboratory (Table 2). 
Accuracy (recovery test) 
Accuracy of the method was studied by recovery 
experiments. The recovery experiments were per-
formed by adding known amounts of the drugs in the 
placebo. The recovery was performed at three levels, 
80, 100 and 120% of the label claim of the tablet (100 
mg of ciprofibrate). The recovery samples were pre-
pared in the aforementioned procedure, and then 5 
mL of ciprofibrate solution were transferred into a 50 
mL volumetric flask and diluted to volume with diluent 
B. Three samples were prepared for each recovery 
level. The solutions were then analyzed, and the per-
centage recoveries were calculated from the calibra-
tion curve. The recovery values for ciprofibrate ranged 
from 98.65 to 100.01%. The average recoveries of 
three levels for ciprofibrate were 99.5% (Table 3). 
Linearity 
The linearity of the response of the drug was 
verified at seven concentration levels, ranging from 
10 to 150% of the targeted level (20 μg mL
-1). Con-
centration standard solutions containing 2-30 μg mL
-1 
of ciprofibrate in each linearity level were prepared. 
Linearity solutions were injected in triplicate. The cali-
bration graphs were obtained by the plotting peak 
area versus the concentration data and were treated 
by least-squares linear regression analysis. The 
equation of the calibration curve for ciprofibrate ob-
tained was y = 56747x + 15156, the calibration graphs 
were found to be linear in the aforementioned con-
centrations. The coefficient of determination was 0.998 
(Table 4). 
Limit of detection and limit of quantification 
(LOD and LOQ) 
The limit of detection (LOD) and limit of quanti-
fication (LOQ) were determined by calibration curve 
method.
11 Specific calibration curve was constructed 
using samples containing the analytes in the range of 
LOD and LOQ. The LOD and LOQ for ciprofibrate in 
LC were 0.24 and 0.73 μg mL
-1, respectively. LOD 
and  LOQ were calculated by using the following 
equations:  
LOD = 3.3Sa/b  
LOQ = 10Sa/b  
Table 2. Result of precision of test method 
Sample number 
Assay of ciprofibrate as % of labeled amount 
Analyst 1 (intra-day precision)  Analyst 2 (inter-day precision) 
1   99.97   99.75 
2   99.87   99.40 
3   99.98   99.23 
4   99.56   99.31 
5   99.45   99.43 
6   99.68   99.13 
Mean   99.75   99.45 
RSD  0.12   0.101 
Table 3. Results of recovery tests of ciprofibrate 
Level of addition, %  Amount added, μg  Recovery, %  Average recovery, % 
80   4.8  98.65  99.5 
100   6  100.01 
120   7.2  99.84 
Table 4. Linearity study of ciprofibrate 
Ser. no.  Concentration, µg/ml  Mean peak area ± SD (n = 6)  RSD / % 
1 2  275833±3445.87  1.24 
2 4  365974±4217.05  1.15 
3 6  491417±5656.12  1.15 
4 8  604837±5995.67  0.99 
5 10  718773±10348.2  1.43 
6 12  835922±5788.57  0.69 P.S. JAIN et al.: STABILITY-INDICATING HPLC DETERMINATION OF CIPROFIBRATE…  CI&CEQ 18 (1) 95−101 (2012) 
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where Sa is the standard deviation of the calibration 
curve and b is the slope of the calibration curve. Pre-
cision at limit of quantification and limit of detection 
was checked by analyzing six test solutions prepared 
at LOQ and LOD levels and calculating the percen-
tage RSD of area. 
Robustness 
In order to determine the robustness of the de-
veloped method, experimental conditions were pur-
posely altered and the resolution between ciprofibrate 
and acid degradation products was evaluated. The 
flow rate of the mobile phase was 1.0 mL min
-1. To 
study the effect of flow rate on the resolution, it was 
changed by 0.2 units from 0.8 to 1.2 mL min
-1. The ef-
fect of percent organic strength on resolution was 
studied by varying methanol from –10 to +10%. The 
resolution in the robustness study was not less than 
3.5 in all conditions. The stability of the standard so-
lutions and the sample solutions was tested at inter-
vals of 24, 48 and 72 h. The stability of solutions was 
determined by comparing results of the assay of the 
freshly prepared standard solutions. The RSD for the 
assay results determined up to 72 h for ciprofibrate 
was 0.53%. The assay values were within 1.5% after 
72 h. The results indicate that the solutions were 
stable for 72 h at ambient temperature. 
CONCLUSIONS 
The developed method is stability-indicating and 
can be used for assessing the stability of ciprofibrate 
bulk drugs and pharmaceutical dosage form. The de-
veloped method is specific, selective, robust, rugged 
and precise. This method can be conveniently used 
for assessing stability assay of selected substances 
and dissolution of tablets containing ciprofibrate in 
quality control laboratory. The study showed that the 
drug was stable for thermal and photo degradation 
conditions, whereas moderately degraded in acid 
(7.54%) and base (4.88%) conditions but highly deg-
raded in the oxidative (58.70%) conditions. 
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NAUČNI RAD
PRIMENA HPLC METODE ZA ODREĐIVANJE 
STABILNOSTI CIPROFIBRATA U 
FARMACEUTSKOJ SUPSTANCI I 
FARMACEUTSKIM PREPARATIMA 
Razvijena je i validirana nova HPLC metoda za kvantitativno određivanje stabilnosti cip-
rofibrata u farmaceutskoj supstanci i farmaceutskim preparatima u prisustvu degrada-
cionih proizvoda. Za razdvajanje i određivanje aktivne supstance i degradacionih proiz-
voda korišćena je RP-HPLC metoda, sa kolonom Ace5-C18 (250 mm×4.6 mm, 5 μm) i 
mobilnom fazom metanol/voda u odnosu 90:10 v/v; komponente su detektovane na 232 
nm. Ciprofibrat je podrvgnut kiseloj i alkalnoj hidrolizi, oksidaciji u 30% H2O2, fotolizi i 
degradaciji pri zagrevanju. Degradacioni proizvodi se dobro razdvajaju od glavnog pika
aktivne susptance. Recovery vrednosti za farmaceutske formulacije su od 98.65 do 
100.01%. Razvijena metoda je validirana na linearnost, tačnost (recovery), preciznost,
proveru pogodnosti sistema, specifičnost i robustnost. 
Ključne reči: ciprofibrat; HPLC; validacija; stabilnost; degradacija. 
 
 